Evidence map›Paper›PMID 38330378›Full record

ArticleJournal of gynecologic oncology2024

Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer.

Takahiro Nozaki, Ikuko Sakamoto, Keiko Kagami, Kenji Amemiya, Yosuke Hirotsu, Hitoshi Mochizuki, Masao Omata

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Takahiro NozakiDepartment of Gynecology, Yamanashi Central Hospital, Kofu, Japan. nozaki-bcwc@ych.pref.yamanashi.jp.ORCID 0000-0001-7191-4174
Ikuko SakamotoDepartment of Gynecology, Yamanashi Central Hospital, Kofu, Japan.ORCID 0000-0002-8990-9899
Keiko KagamiDepartment of Gynecology, Yamanashi Central Hospital, Kofu, Japan.ORCID 0000-0002-8780-2254
Kenji AmemiyaGenome Analysis Center, Yamanashi Central Hospital, Kofu, Japan.ORCID 0000-0003-4223-0528
Yosuke HirotsuGenome Analysis Center, Yamanashi Central Hospital, Kofu, Japan.ORCID 0000-0002-8002-834X
Hitoshi MochizukiGenome Analysis Center, Yamanashi Central Hospital, Kofu, Japan.ORCID 0000-0002-1145-0969
Masao OmataGenome Analysis Center, Yamanashi Central Hospital, Kofu, Japan.ORCID 0000-0001-7977-1497
Yamanashi Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the useful biomarker for predicting the effects of poly-(ADP ribose)-polymerase (PARP) inhibitors in Japanese patients with ovarian cancer.

methodsWe collected clinical information and performed molecular biological analysis on 42 patients with ovarian, fallopian tube, and primary peritoneal carcinomas who received PARP inhibitors.

resultsAmong the analyzed patients with ovarian cancer, 23.8% had germline

conclusionWe found that HRRm can be a useful biomarker for predicting the effects of PARP inhibitors in treating ovarian cancer and that the PFI can also be useful in recurrent ovarian cancer.

Indexed as

Biomarkers, TumorOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsProgression-Free SurvivalAdultAgedAged, 80 and overFallopian Tube NeoplasmsFemaleGenomic InstabilityGerm-Line MutationHumansMiddle AgedNeoplasm Recurrence, LocalPeritoneal NeoplasmsRecombinational DNA RepairBiomarkers, TumorPoly(ADP-ribose) Polymerase InhibitorsGenomicsHomologous RecombinationMutationOvarian Cancer

Identifiers

PMID38330378
PMCPMC11262903
OpenAlexW4391452524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.